368 results about "Protective antigen" patented technology

A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.

The invention provides a SARS-CoV-2 vaccine using human type-5 replication-defective adenovirus as a vector. The vaccine uses E1 and E3 to be combined with replication-defective human type-5 adenovirus as the vector and HEK293 cells integrating adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is the 2019 SARS-CoV-2 S protein gene (Ad5-nCoV) which is subjected to optimization design. After the S protein gene is optimized, the expression level in transfected cells is increased significantly. The vaccine has good immunogenicity in mouse and guinea pig models, andcan induce a body to produce a strong cellular and humoral immune response in a short time. Studies on the protective effect of hACE2 transgenic mice show that after 14 days of single immunization ofAd5-nCoV, the viral load in lung tissue can be significantly reduced, and it is indicated that the vaccine has a good immunoprotective effect on the 2019 SARS-CoV-2. In addition, the vaccine is quick, simple and convenient to prepare, and can be mass-produced in a short period of time to respond to sudden outbreaks.

The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

A novel i-antigen protein from Ichthyophthirius multifiliis is effective to induce a protective immune response in fish. The invention includes antigenic and membrane-targeting sequences of i-antigen proteins, nucleic acid molecules that encode antigenic or membrane-targeting portions of i-antigen proteins, DNA and protein subunit vaccines, methods of inducing an immune response in fish and methods for detection and characterization of I. multifiliis.

The present invention provides one kind of genetic engineering multivalent subunit vaccine for preventing and treating human helicobacter pylori infection and its preparation process. The vaccine consists of active helicobacter pylori UreB fragment UreB414 as the central antigen component, other combined protective antigens, and intramolecular or extramolecular adjuvant. Compared with univalent vaccine, the multivalent combined vaccine can stimulate the body to generate more powerful and more comprehensive helicobacter pylori resisting specific immune reaction.

The present invention relates to a live cytadherence-deficient M. gallisepticum strain that does not express at least two of three proteins, the Gap-A molecule, crnA protein, and the 45 kDa protein, expressed by wildtype M. gallisepticum Strain R and its use as a vaccine for preventing and protecting birds, especially chickens and turkeys against the respiratory diseases attendant with wildtype Mycoplasma gallispeticum infection. The invention also relates to the use of the vaccine as a vector for the delivery of genes encoding protective antigens from other bacterial and viral avian pathogens, such as avian influenza virus. There is also disclosed a method for identifying the attenuated cytadherence-deficient M. gallisepticum Rhigh or a strain thereof.

A variety of modified Bacillus anthracis bacteria useful in vaccines are provided. For instance, asporogenic strains of Bacillus anthracis are provided. In addition, Bacillus anthracis strains attenuated in their ability to repair their nucleic acid, such as in their nucleic acid excision repair ability or recombination repair ability, are provided. Strains expressing an antigen, such as protective antigen, under the control of a heterologous promoter and/or an inducible promoter are also provided. Bacillus anthracis bacteria comprising mutations in toxin genes are further provided. Vaccine compositions comprising the bacteria, methods of making the modified strains, and methods of using the vaccines are also provided.

The invention discloses a recombinant low-virulent vaccine strain of chicken infectious bursal disease viruses (IBDV) and application thereof. In the invention, a major protective antigen gene VP2 of an epidemic superhigh virulent strain is cloned, the nucleotide of the gene VP2 is modified by mutation and then used for replacing a corresponding segment of a Gt genome of a low-virulent strain of the IBDV, so that the infectious clone of a recombinant genome of the IBDV is constructed, and the recombinant low-virulent vaccine strain is saved and identified by using an IBDV reverse genetic operation system. The microbial collection number of the vaccine strain is CGMCC No.3749. The recombinant low-virulent vaccine strain of the invention has high replicability, genetic stability and safety. The immune effect of the low-virulent vaccine strain of the invention is as good as that of the medium-virulent vaccine strain, but is superior to that of the low-virulent vaccine strain. The biological safety of the low-virulent vaccine strain of the invention is superior to that of the medium-virulent vaccine strain. As the vaccine strain, the recombinant low-virulent vaccine strain of the invention has the characteristics of high efficiency and low toxicity, is a good candidate vaccine strain and can be used for controlling chicken infectious bursal disease.

The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.

The invention relates to an adjuvant for enhancing a fish vaccine immunization effect and an application thereof. The adjuvant for enhancing the fish vaccine immunization effect is characterized in that an immune potentiator is extracted from Astragalus mongholicus as a leguminous plant or effective components of the Astragalus mongholicus, comprising Astragaloside and Astragalus polysacharin, and natural products or manually modified products or manually synthetic products comprising the Astragaloside and the Astragalus polysacharin can be adopted to serve as the effective components. The adjuvant is capable of increasing the specific immune protection rate after vaccine component immunization is finished. When the adjuvant is applied, a vaccine can comprise the following components: any one or more than one of expression products of inactivated pathogens, bacterial ghost components, hypotoxic pathogens, attenuated pathogens, protective antigens, antigen subunits, antigen determinants or antigen gene expression vectors of bacteria, viruses and parasites. When in use, the adjuvant can be mixed with the components of the vaccine for application, also cannot be mixed with the components of the vaccine for application and also can be applied with the vaccine at different time.

The invention provides construction of a lactobacillus acidophilus S-layer protein surface display system, which belongs to the field of biotechnology. The construction is characterized in that gene acquisition comprises (1) PCR amplification, (2) the connection of a SlpA gene and a pMD18-TVector system and (3) the identification of cloning plasmid pMD18T-S, and the construction comprises (1) theacquisition of a target gene and a double-labeling expression vector, (2) the connection and transformation of the double-labeling expression vector and SlpA, (3) the identification of a surface display vector system and (4) the detection of the anchored expression situation of S-layer protein on recombinant surface. The construction has the advantages that: 1, the constructed vector can be used to be transformed into S-layer protein gene defect lactobacillus to study the formation mechanism of lactobacillus S-layer protein; and 2, by utilizing a DNA recombination technique, protective antigengenes of pathogens are fused with lactobacillus S-layer protein on the surface display vector.

The invention discloses a recombinant porcine epidemic diarrhea virus (PEDV) lactococcus lactis and its construction method and use. The construction method comprises the following steps of carrying out RT-PCR amplification to obtain a major protective antigen COE gene sequence of PEDV, carrying out clone sequencing, designing expression primers according to the sequencing result and expression vector characteristics, carrying out amplification of a PEDV COE coding sequence, connecting the PEDV COE coding sequence to a lactococcus lactis expression vector pNZ8149, and carrying out electrotransformation of the lactococcus lactis expression vector pNZ8149 into a lactococcus lactis NZ3900 cell to obtain the recombinant PEDV lactococcus lactis. The recombinant PEDV lactococcus lactis is induced by 1ng/mL of Nisin and through SDS-PAGE and Western blot analysis, a main s protein of the PEDV is expressed. An expressed recombinant PEDV lactococcus lactis vector oral vaccine can irritate production of humoral immunity and certain cellular immunity of mice. The recombinant PEDV lactococcus lactis has wide application prospects in drugs such as a PEDV vaccine.

The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.

The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.

The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4⁺ T cell response. The responsive CD4⁺ T cell are primarily T_H1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.

Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV backround of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.

The invention relates to an adjuvant for improving the immunization effect of Edwardsiella vaccine and a use method of the adjuvant. The adjuvant is characterized by being extracted from raw materials including grain, yeast and a part of fungi or algae. The effective component of the adjuvant is beta-1,3-glucan or the natural, artificially modified or synthetic product of the beta-1,3-glucan. The adjuvant can be used for increasing the specific immune protection ratio of any one or more inculcated Edwardsiella vaccine antigens including the inactivated bacteria, the bacteria disintegration component, the less-virulent strain, the attenuated strain, the protective antigen, the antigen subunit, the antigenic determinant clusters or the expression product of the antigen cell expression vector of the Edwardsiella, can be used together or not together with the vaccine antigen and can be prepared into a single preparation which is used together with the vaccine antigen.

The invention discloses application of protein Rh054_01780 to rickettsia heilongjiangensis-resistant immune protection, and provides application of the protein Rh054_01780 to preparation of a vaccine for far eastern spotted fever, a vaccine for rickettsia heilongjiangensis, a protective antigen for far eastern spotted fever, or a protective antigen for rickettsia heilongjiangensis. The protein Rh054_01780 is (a) or (b), wherein (a) is a protein which has an amino acid sequence shown as a sequence 1 in a sequence table; and (b) is a protein which is formed by substituting and/or deleting and/or adding one or more amino acid residues in the amino acid sequence shown as the sequence 1 in the sequence table, has the same function and is derived from the sequence 1. Compared with a mycoproteinvaccine, a vaccine prepared from the protein Rh054_01780 has the advantages of simple and convenient preparation method, low cost, high yield, safety and the like; and the protein Rh054_01780 has significant value in the aspect of epidemic prevention and treatment of far eastern spotted fever.